Research shows overall survival benefit for patients with Stage III soft tissue sarcomas

May 30, 2014

Fox Chase Cancer Center researchers have carried out the first retrospective analysis of adjuvant chemotherapy's impact on overall survival in patients with stage III soft tissue sarcomas (STS), adjusted for socioeconomic status and other variables. The findings show that regardless of socioeconomic status and comorbidities, adjuvant chemotherapy improved survival by approximately 23 percent in stage III STS. Study leader Sujana Movva, MD, Medical Oncologist at Fox Chase, will present the findings the 50th Annual Meeting of the American Society of Clinical Oncology.

Previous meta-analyses have demonstrated that adjuvant confers a small absolute to with STS, which arises in the tissues that support other parts of the body. Muscle, fat, blood vessels, nerves, tendons and the tissue surrounding joints are all soft tissues in which sarcomas can arise.

STS is uncommon but can be aggressive. About 12,000 people are diagnosed with STS in the United States every year, according to the National Cancer Institute, and stage III disease has a five-year survival rate of only 50 percent. Dr. Movva noted that medical oncologists across the United States treat these patients differently.

"We really wanted to show that for these aggressive sarcomas, which have a high likelihood of becoming metastatic disease, there's a high degree of variability for who gets adjuvant chemotherapy," she said.

Dr. Movva and her colleagues analyzed medical records of 12,198 individuals diagnosed with stage III STS between 1998 and 2010 from the National Cancer Data Base (NCDB), a collaboration between the Commission on Cancer of the American College of Surgeons and the American Cancer Society. They excluded patients who had not undergone surgery for primary tumor resection and those who had tumor histologies conventionally considered to be resistant to o chemotherapy.

The NCDB, established in 1989, consolidates outcomes data from 29 million records—representing more than three-quarters of all newly diagnosed cancer cases—from cancer centers in the United States. Dr. Movva said the size of the database allowed her and her collaborators to gather enough data for a strong analysis.

"This is a lot more patients than we usually look at in sarcoma studies," she said. "Having 12,000 patients to look at is not a number we're used to."

Despite the potential benefits of adjuvant chemotherapy, she and her team found that only 29 percent of the high risk patients they studied had received the treatment. In both univariate and multivariate analyses, the Fox Chase team identified a variety of individual factors each associated with a higher likelihood of having been treated with chemotherapy. Patients who were younger than 40, were covered by private insurance, earned a higher income, had no comorbidities, had synovial histology or had tumors measuring more than 10 centimeters were more likely to have received chemotherapy.

Dr. Movva and her team found an overall survival benefit from chemotherapy. Before they adjusted for any variables, the median overall survival for patients treated with adjuvant chemotherapy was 83.9 months, compared to 48.5 months for patients not treated. Their adjusted analysis took into account 15 total different socioeconomic and tumor factors, including race, age, comorbid conditions and insurance status. The adjusted benefit also showed a significant overall survival benefit (HR=0.77) associated with .

Dr. Movva noted that a previous, meta-analysis of all STS patient data estimated the absolute benefit of chemotherapy to be only about 6-11 percent depending on chemotherapy used. —Medical oncologists who treat their patients according to that estimate—especially those not in the sarcoma research community—may think that such a low benefit doesn't justify the use of chemotherapy.

However, "among stage III patients, there are some at very high risk for metastatic disease and whoare also fit enough to benefit from chemotherapy," she said.

Dr. Movva thinks that the field is moving toward better identification of those high-risk patients most likely to respond to more aggressive treatment.

"I think the state of sarcoma research is very positive and encouraging," she said. "We have a larger understanding than we used to of how heterogeneous the disease is, and we are going to make significant strides in this disease over the next several years."

Explore further: More patients with ovarian cancer are receiving chemotherapy before surgery

Related Stories

More patients with ovarian cancer are receiving chemotherapy before surgery

May 30, 2014
The use of chemotherapy before surgery to remove ovarian cancer has increased dramatically in recent decades, particularly among certain patients, according to a new analysis from Fox Chase Cancer Center that will be presented ...

Chemotherapy before or after surgery for high-risk bladder cancer improves survival, but is not routinely administered

April 14, 2014
Contrary to treatment guidelines for high-risk bladder cancer, chemotherapy before or after surgery is not commonly used in routine clinical practice. The findings are published early online in Cancer, a peer-reviewed journal ...

Hepatitis C reactivation doesn't worsen survival for HIV+ patients diagnosed with lymphoma

May 30, 2014
More than a quarter of HIV+ patients are also infected with the Hepatitis C virus (HCV), which may complicate treatment and care decisions after a cancer diagnosis. The specifics of those complications haven't been well-researched ...

Long-term follow-up shows need for new chemotherapy strategies for rectal cancer

January 22, 2014
Appearing in Lancet Oncology, long term results of EORTC trial 22921 with 10.4 years median follow-up show that 5-FU (fluorouracil) based adjuvant chemotherapy after preoperative (chemo)-radiotherapy for patients with cT3-resectable ...

Chemotherapy's effect on overall survival seems to increase based on tumor size

May 15, 2012
The most recent research released in June's Journal of Thoracic Oncology indicates there might be a positive correlation between tumor size and adjuvant platinum based chemotherapy in surgically resected patients with node ...

Getting chemo first may help in rectal cancer

May 15, 2014
(Medical Xpress)—A new phase II study to be presented at the annual meeting of the American Society for Clinical Oncology finds that if chemotherapy is offered before radiation and surgery, more patients will be able to ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.